Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
Makaleler > Tam Makale · 2021
Yazarlar: Aykut Bahceci, SEMRA PAYDAŞ, Naziye Ak, Ferhat Ferhatoglu, Pinar Mualla Saip, GÜLŞAH SEYDAOĞLU, Mehmet BİLİCİ, Melih ŞİMŞEK, Salim Başol TEKİN, Zuleyha Calikusu, Sinan Yavuz, AHMET BİLGEHAN ŞAHİN, ERDEM ÇUBUKÇU, TÜRKKAN EVRENSEL, Serkan Degirmencioglu, Atike Gokcen Demiray, PERRAN FULDEN YUMUK, Ozkan Alan, Duygu Ilke Cikman, Fuat Hulusi Demirelli, Osman Kostek, Ali Gokyer, Mutlu Dogan, Oznur Bal, Burcu ÇAKAR, Erhan GÖKMEN, Deniz Yamac, Taner Korkmaz, Altay Aliyev, ÖZGE KESKİN, Semiha Urvay, MAHMUT BÜYÜKŞİMŞEK, Cemile Karadeniz, Birol Yildiz, Havva Yesil Cinkir, Hacer Demir, Ismail Beypinar, Cengiz Karacin, Kadir Eser, Meltem Baykara, SAADETTİN KILIÇKAP, Kerem Okutur, Gulcan Bulut, Ali Alkan, Erkan Arpaci, Kezban Nur Pilanci, Atakan Demir, Deniz Isik, Nilgun Yildirim
Cancer Investigation, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2021, cilt 39, ss 473-481
DOI: 10.1080/07357907.2021.1933011
Özet
Aim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey.Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3–4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%).Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.